Journal: Brain, behavior, and immunity
Article Title: TLR2 immunotherapy suppresses neuroinflammation, tau spread, and memory loss in rTg4510 mice.
doi: 10.1016/j.bbi.2024.08.002
Figure Lengend Snippet: Fig. 1. TLR2 knockout reduces tau pathology and alleviates cognitive functions in rTg4510 mice. (A) Differential RNA expression of TLRs in AD brains compared to cognitively normal controls. Log2 fold changes are indicated. ACC, anterior cingulate cortex; CBE, cerebellum; DLPFC, dorsolateral prefrontal cortex; FP, frontal pole; IFG, inferior frontal gyrus; PCC, posterior cingulate cortex; PHG, parahippocampal gyrus; STG, superior temporal gyrus; TCX, temporal cortex. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. (B-D) Tlr2 KO ameliorates cognitive impairment in rTg4510 mice. The 6-month-old mice (tTA/WT, tTA/Tlr2 KO, rTg4510/ WT, rTg4510/Tlr2 KO) were analyzed with the Y-maze test [B, two-way ANOVA with Tukey test, n (male, female) = 10 (7, 3); 10 (2, 8); 8 (6, 2); 11 (4, 7)], novel object recognition test [C, two-way ANOVA with Tukey test, n (male, female) = 8 (5, 3); 7 (2, 5); 6 (4, 2); 7 (2, 5)], and passive avoidance test [D, paired t-test, n (male, female) = 10 (7, 3); 10 (2, 8); 9 (6, 3); 11 (4, 7)]. (E-G) Tlr2 KO reduces tau pathology and microglial activation in rTg4510 mice. Immunohistochemistry of AT8 and Iba1 in the frontal cortex, dentate gyrus, and entorhinal cortex (E). Scale bar, 20 μm. Quantification of AT8 signal intensities (F) and the number of Iba1- positive cells (G). Two-way ANOVA with Tukey test, n = 7, 6, 3, 5. Data are represented as mean ± SEM. N.S., not significant.
Article Snippet: The primary antibodies used in the study: Tomaralimab (Amyloid Solution Inc., 1:250), anti-human TLR2 (Cell Signaling Technology #12276, 1:1000), anti-mouse TLR2 (Cell Signaling Technology #13744, 1:1000), anti-human tau HT7 (Invitrogen #MN1000, 1:1000), antiTau4R (Cell Signaling Technology #30328, 1:1000), anti-phospho-tau AT8 (Invitrogen #MN1020, 1:500), anti-Iba1 (GeneTex #GTX635400, 1:500), anti-Iba1 (Wako #019-19741, 1:1000), anti-MAP2 (Cell Signaling Technology #4542, 1:500), anti-NeuN (Millipore #MAB377, 1:1000), anti-GFAP (Cell Signaling Technology #80788, 1:1000), antiMyD88 (Cell Signaling Technology #50010, 1:1000), anti-NLRP3 (Cell Signaling Technology #15101, 1:1000), anti-β-actin (Santa Cruz Biotechnology #sc-47778, 1:1000), anti-GFP (Santa Cruz Biotechnology #sc-9996, 1:3000), anti-His-Tag (Cell Signaling Technology #2365, 1:1000).
Techniques: Knock-Out, RNA Expression, Activation Assay, Immunohistochemistry